mRNA-1018 for H5 Only / Moderna - LARVOL DELTA

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P3 | N=4050 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults. (PubMed, Clin Infect Dis) - "Vaccine candidates were sufficiently well-tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted for pandemic preparedness."

Journal • P1/2 data • Fatigue • Infectious Disease • Influenza • Pain • Respiratory Diseases

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P3 | N=4000 | Recruiting | Sponsor: ModernaTX, Inc.

New P3 trial • Infectious Disease • Influenza • Respiratory Diseases

Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study (IDWeek 2025) - No abstract available

Clinical • P1/2 data • Infectious Disease • Influenza

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1504 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Influenza • Respiratory Diseases

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults (clinicaltrials.gov) - P1/2 | N=1500 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Influenza • Respiratory Diseases